Screener
Ultragenyx Pharmaceutical RARE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (75) | (108) | (244) | (251) |
| Interest income | 5 | 6 | 11 | 13 |
| Non-cash interest expense on liabilities for sales of future royalties | (22) | (14) | (43) | (28) |
| Other income | 1 | 2 | 1 | 2 |
| Loss before income taxes | (91) | (114) | (275) | (264) |
| Provision for income taxes | (1) | (1) | (2) | (2) |
| Net loss | $(92) | $(115) | $(277) | $(266) |
| Net loss per share, basic and diluted | $(0.90) | $(1.17) | $(2.73) | $(2.73) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's other income (expense)?
- Ultragenyx Pharmaceutical (RARE) reported other income (expense) of $1M in Q2 2026.
- How has Ultragenyx Pharmaceutical's other income (expense) changed year-over-year?
- Ultragenyx Pharmaceutical's other income (expense) decreased by 50.0% year-over-year, from $2M to $1M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Ultragenyx Pharmaceutical's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude